General Structure Information 4lvt BCL2 bcl_2-navitoclax (abt-263) complex 2.05Å AUTH A.J.SOUERS,J.D.LEVERSON,E.R.BOGHAERT,S.L.ACKLER,N.D.CATRON,AUTH 2 J.CHEN,B.D.DAYTON,H.DING,S.H.ENSCHEDE,W.J.FAIRBROTHER,AUTH 3 D.C.HUANG,S.G.HYMOWITZ,S.JIN,S.L.KHAW,P.J.KOVAR,L.T.LAM,AUTH 4 J.LEE,H.L.MAECKER,K.C.MARSH,K.D.MASON,M.J.MITTEN,P.M.NIMMER,AUTH 5 A.OLEKSIJEW,C.H.PARK,C.M.PARK,D.C.PHILLIPS,A.W.ROBERTS,AUTH 6 D.SAMPATH,J.F.SEYMOUR,M.L.SMITH,G.M.SULLIVAN,S.K.TAHIR,AUTH 7 C.TSE,M.D.WENDT,Y.XIAO,J.C.XUE,H.ZHANG,R.A.HUMERICKHOUSE,AUTH 8 S.H.ROSENBERG,S.W.ELMORETITL ABT-199, A POTENT AND SELECTIVE BCL-2 INHIBITOR, ACHIEVESTITL 2 ANTITUMOR ACTIVITY WHILE SPARING PLATELETS.REF NAT.MED. (N.Y.) V. 19 202 2013REFN ISSN 1078-8956PMID 23291630DOI 10.1038/NM.3048 Variant Set Distributions Ripley’s K Analysis […]